---
title: "Tempus AI, Inc. (TEM.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TEM.US/overview.md"
symbol: "TEM.US"
name: "Tempus AI, Inc."
parent: "https://longbridge.com/en/quote/TEM.US.md"
datetime: "2026-04-04T23:57:07.921Z"
locales:
  - [en](https://longbridge.com/en/quote/TEM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TEM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TEM.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TEM.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TEM.US/overview.md)


# Tempus AI, Inc. (TEM.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Address | 600 West Chicago Avenue, Suite 510, Chicago, Illinois, United States |
| Website | [www.tempus.com](https://www.tempus.com) |

## Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.

## Key Executives

| Name | Title |
|------|-------|
| Eric P. Lefkofsky | Co-Founder, CEO, President & Chairman |
| Ryan Fukushima | Chief Operating Officer |
| Andrew Polovin | Executive VP, General Counsel & Secretary |
| James Rogers | Chief Financial Officer |
| Ryan M. Bartolucci | Chief Accounting Officer |
| Peter J. Barris | Independent Director |
| Theodore J. Leonsis | Independent Director |
| Eric D. Belcher | Independent Director |
| Scott Gottlieb | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Eric P. Lefkofsky | 23.61% | 2026-03-26 |
| Bradley Alan Keywell | 7.19% | 2025-08-08 |
| The Vanguard Group, Inc. | 5.74% | 2025-12-31 |
| ARK Investment Management LLC | 5.28% | 2026-02-28 |
| Baillie Gifford & Co. | 4.89% | 2025-12-31 |
| Kimberly Keywell | 4.51% | 2025-09-30 |
| BlackRock, Inc. | 4.20% | 2025-12-31 |
| Catalytic Wealth RIA, LLC | 3.78% | 2025-12-31 |
| SoftBank Group Corp. | 3.02% | 2025-12-31 |
| Nikko Asset Management Co., Ltd. | 1.96% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Medical Labs & Research | 1271789000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Tempus AI, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Medical Labs & Research",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 1271789000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**